Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Allergy and Asthma Reports
Published in: Current Allergy and Asthma Reports 1/2011

01-02-2011

Interleukin-33 in Asthma: How Big of a Role Does It Play?

Authors: Larry Borish, John W. Steinke

Published in: Current Allergy and Asthma Reports | Issue 1/2011

Login to get access

Abstract

In complex disorders such as asthma and allergic disease, the goal for developing disease-modifying biotherapeutics is to find a target that is a central instigator of immunologic activity. Interleukin (IL)-33 seems to be such a molecule, as it is one of the earliest-released signaling molecules following epithelial damage and can orchestrate the recruitment and activation of the cells responsible for disease. Unregulated IL-33 activity leads to activation of T-helper type 2 cells, mast cells, dendritic cells, eosinophils, and basophils, ultimately leading to increased expression of cytokines and chemokines that define the disease. As such, IL-33 is an attractive candidate for therapeutic intervention with the goal of ameliorating disease. This review focuses on the role of IL-33 in promoting and maintaining the asthma phenotype.
Literature
1.
Barksby HE, Lea SR, Preshaw PM, Taylor JJ: The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol 2007, 149:217–225.CrossRefPubMed
2.
Sims JE, Nicklin MJ, Bazan JF, et al.: A new nonmenclature for IL-1-family genes. Trends Immunol 2001, 22:536–537.CrossRefPubMed
3.
Robinson D, Shibuya K, Mui A, et al.: IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB. Immunity 1997, 7:571–581.CrossRefPubMed
4.
5.
Schmitz J, Owyang A, Oldham E, et al.: IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479–490.CrossRefPubMed
6.
•• Luthi AU, Cullen SP, McNeela EA, et al.: Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 2009, 31:84–98, It was believed that IL-33 was activated by caspases, similar to other members of the IL-1 family; however, this article demonstrated that IL-33 was active in the uncleaved form and was only released following necrosis caused by cell damage.CrossRefPubMed
7.
Carriere V, Roussel L, Ortega N, et al.: IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A 2007, 104:282–287.CrossRefPubMed
8.
Maier JA, Statuto M, Ragnotti G: Endogenous interleukin 1 alpha must be transported to the nucleus to exert its activity in human endothelial cells. Mol Cell Biol 1994, 14:1845–1851.PubMed
9.
Buryskova M, Pospisek M, Grothey A, et al.: Intracellular interleukin-1alpha functionally interacts with histone acetyltransferase complexes. J Biol Chem 2004, 279:4017–4026.CrossRefPubMed
10.
Dunne A, O’Neill LA: The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2003, 2003:re3.
11.
Klemenz R, Hoffman S, Werenskiold AK: Serum- and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen. Proc Natl Acad Sci U S A 1989, 86:5708–5712.CrossRefPubMed
12.
Tominaga A: A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett 1989, 258:301–304.CrossRefPubMed
13.
Pecaric-Petkovic T, Didichenko SA, Kaempfer S, et al.: Human basophils and eosinophils are the direct target leukocytes of the novel IL-1-family member IL-33. Blood 2009, 113:1396–1397.
14.
Smithgall MD, Comeau MR, Yoon BR, et al.: IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol 2008, 20:1019–1030.CrossRefPubMed
15.
Neill DR, Wong SH, Bellosi A, et al.: Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010, 464:1367–1370.CrossRefPubMed
16.
Rossler U, Thomassen E, Hultner L, et al.: Secreted and membrane-bound isoforms of T1, an orphan receptor related to IL-1-binding proteins, are differently expressed in vivo. Dev Biol 1995, 168:86–97.CrossRefPubMed
17.
Chackerian AA, Oldham ER, Murphy EE, et al.: IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007, 179:2551–2555.PubMed
18.
Lohning M, Stroehmann A, Coyle AJ, et al.: T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A 1998, 95:6930–6935.CrossRefPubMed
19.
Xu D, Chan WL, Leung BP, et al.: Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 1998, 187:787–794.CrossRefPubMed
20.
Coyle AJ, Lloyd CM, Tian J, et al.: Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med 1999, 190:895–902.CrossRefPubMed
21.
Townsend MJ, Fallon PG, Matthews DJ, et al.: T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med 2000, 191:1069–1075.CrossRefPubMed
22.
Kurowska-Stolarska M, Kewin P, Murphy G, et al.: IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 2008, 181:4780–4790.PubMed
23.
Komai-Koma M, Xu D, Li Y, et al.: IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol 2007, 37:2779–2786.CrossRefPubMed
24.
• Rank MA, Kobayahi T, Kozaki H, et al.: IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol 2009, 123:1047–1054, This article demonstrated that DCs respond to IL-33 through the ST2 receptor. When these stimulated DCs were cultured with naïve T cells, they were able to induce expression of IL-5 and IL-13.CrossRefPubMed
25.
Mayuzumi N, Matsushima H, Takashima A: IL-33 promotes DC development in BM culture by triggering GM-CSF production. Eur J Immunol 2009, 39:3331–3342.CrossRefPubMed
26.
Iikura M, Suto H, Kajiwara N, et al.: IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest 2007, 87:971–978.CrossRefPubMed
27.
Moulin D, Donze O, Talabot-Ayer D, et al.: Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 2007, 40:216–225.CrossRefPubMed
28.
Allakhverdi Z, Smith DE, Comeau MR, Delespesse G: Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 2007, 179:2051–2054.PubMed
29.
Drube S, Heink S, Walter S, et al.: The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells. Blood 2010, 115:3899–3906.CrossRefPubMed
30.
Allakhverdi Z, Comeau MR, Smith DE, et al.: CD34+ hemopoietic progenitor cells are potent effectors of allergic inflammation. J Allergy Clin Immunol 2009, 123:472–478.CrossRefPubMed
31.
Pushparaj PN, Tay HK, H’ng SC, et al.: The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci U S A 2009, 106:9773–9778.CrossRefPubMed
32.
Hayakawa H, Hayakawa M, Kume A, Tominaga S: Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 2007, 282:26369–26380.CrossRefPubMed
33.
• Kearley J, Buckland KF, Mathie SA, Lloyd CM: Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am J Respir Crit Care Med 2009, 179:772–781, Using a murine model of allergic disease, these authors demonstrated that blockade of ST2 prevented development of airway hyperreactivity and an increase of Th2 cells into the lung. IL-33 levels were increased during active lung inflammation.CrossRefPubMed
34.
Cherry WB, Yoon J, Bartemes KR, et al.: A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol 2008, 121:1484–1490.CrossRefPubMed
35.
Chow JY, Wong CK, Cheung PF, Lam CW: Intracellular signaling mechanisms regulating the activation of human eosinophils by the novel Th2 cytokine IL-33: implications for allergic inflammation. Cell Mol Immunol 2010, 7:26–34.CrossRefPubMed
36.
Suzukawa M, Iikiura M, Koketsu R, et al.: An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol 2008, 181:5981–5989.PubMed
37.
Prefontaine D, Nadigel J, Chouiali F, et al.: Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol 2010, 125:752–754.CrossRefPubMed
38.
Reh DD, Wang Y, Ramanathan M Jr, Lane AP: Treatment-recalcitrant chronic rhinosinusitis with polyps is associated with altered epithelial cell expression of interleukin-33. Am J Rhinol Allergy 2010, 24:105–109.CrossRefPubMed
Metadata
Title
Interleukin-33 in Asthma: How Big of a Role Does It Play?
Authors
Larry Borish
John W. Steinke
Publication date
01-02-2011
Publisher
Current Science Inc.
Published in
Current Allergy and Asthma Reports / Issue 1/2011
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-010-0153-8

Other articles of this Issue 1/2011

Current Allergy and Asthma Reports 1/2011 Go to the issue

ReviewPaper

Exercise-Induced Anaphylaxis: An Update on Diagnosis and Treatment

ReviewPaper

Perspectives on Anaphylaxis Epidemiology in the United States with New Data and Analyses

ReviewPaper

Cryopyrin-Associated Periodic Syndrome: An Update on Diagnosis and Treatment Response

ReviewPaper

The Role of the Histamine H4 Receptor in Atopic Dermatitis

ReviewPaper

Racial Disparities in Pediatric Asthma: A Review of the Literature

ReviewPaper

Innate Signaling in Otitis Media: Pathogenesis and Recovery